Last reviewed · How we verify
Insulin degludec 100 U/mL
Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin degludec 100 U/mL |
|---|---|
| Also known as | Tresiba |
| Sponsor | Sanofi |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin degludec is a ultra-long-acting insulin analog designed to provide steady, peakless insulin levels over 24+ hours. It binds to the human insulin receptor with the same affinity as human insulin, activating downstream signaling that facilitates glucose transport into muscle and adipose tissue, inhibits gluconeogenesis in the liver, and promotes anabolic effects. The extended duration results from multi-hexamer formation in subcutaneous tissue, creating a depot effect that provides consistent glycemic control with once-daily dosing.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (PHASE4)
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (PHASE3)
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (PHASE3)
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (PHASE3)
- Degludec Glargine U300 Hospital Study (NA)
- A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes (PHASE3)
- A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin degludec 100 U/mL CI brief — competitive landscape report
- Insulin degludec 100 U/mL updates RSS · CI watch RSS
- Sanofi portfolio CI